Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobevibart+Elebsiran vs Bulevirtide in chronic HDV infection
NCT07142811Phase 2Active, not recruiting
- Sponsor
- Vir Biotechnology
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Conjugated siRNA, Monoclonal Antibodies, Chemically Modified siRNA
- Countries
- 11
01
Overview
A Phase 2 trial of tobevibart, elebsiran in chronic hepatitis D, sponsored by Vir Biotechnology. Started Aug 2025; status: active, not recruiting.
02
Drugs
tobevibartelebsiran
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT07142811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142811.